Angle PLC Announces Change of Adviser

Rhea-AI Summary

ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the appointment of Cavendish Capital Markets Limited as its new Nominated Adviser and Sole Broker, effective immediately.

The company, which focuses on innovative solutions for research, drug development, and clinical oncology, made this change in its advisory relationships to support its ongoing business operations. The appointment demonstrates ANGLE's commitment to maintaining strong market relationships and corporate governance standards.

APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER

GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has appointed Cavendish Capital Markets Limited as the Company's Nominated Adviser and Sole Broker with immediate effect.

For further information:

ANGLE plc Andrew Newland, Chief Executive Ian Griffiths, Finance Director	+44 (0) 1483 343434
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales)	+44 (0) 20 7220 0500
FTI Consulting Simon Conway, Ciara Martin, Sam Purewal Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix^® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix^® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.

Over 115 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on ACCESS Newswire

FAQ

Who is ANGLE plc's new Nominated Adviser and Broker as of September 2025?

Cavendish Capital Markets Limited has been appointed as ANGLE plc's Nominated Adviser and Sole Broker, effective immediately.

What does ANGLE plc (OTCQX:ANPCY) specialize in?

ANGLE plc is a world-leading liquid biopsy company that specializes in circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology.

When did ANGLE plc announce their new advisory appointment?

ANGLE plc announced the appointment of their new Nominated Adviser and Sole Broker on September 9, 2025.

Who are the key contacts for ANGLE plc's corporate communications?

Key contacts include Andrew Newland (Chief Executive) and Ian Griffiths (Finance Director), along with representatives from Cavendish Capital Markets and FTI Consulting.